Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia +61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 1 ASX Announcement HARNESS-1 Cleared to Escalate RC220 to 100 mg/m2 § HARNESS-1 Safety Review Committee has reviewed all safety data from...
HARNESS-1 First Cohort Cleared
Filed with ASX · · 6 pages · English
Release
Earlier from Racura Oncology
- CPACS Trial Opens for RC220 Patient Enrolment in Korea
- First HARNESS-1 Patient Safely Treated with RC220
- June 2026 Quarterly Activities Report and Appendix 4C
- Bellberry Ethics Approval Activates New HARNESS Trial Sites
- Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology